Popular Articles

ImmuneRegen BioSciences Confirms Homspera's Therapeutic Anti-Influenza Effect On Pandemic H1N1 Influenza Virus After Oral Administration
ImmuneRegen BioSciences(R), a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBS), reports preliminary evidence that its selective Neurokinin 1-receptor agonist Homspera(R) is both active on oral administration and provides therapeutic effects against the current pandemic H1N1 virus infection.

ZIOPHARM Presents Positive Data From Phase I Study Of Palifosfamide In Combination With Doxorubicin At ASCO
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced that it presented final data from a Phase I study of palifosfamide (ZymafosTM) in combination with doxorubicin at the 45th Annual American Society of Clinical Oncology (ASCO) meeting held in Orlando, FL, May 29th to June 2nd.
News of the day
Calif. Budget Cuts Threaten Prenatal Health Program For Women, Teens
County public health officials in California say proposed budget cuts could hurt or end the state"s Maternal, Child and Adolescent Health Program, which provides care for high-risk women and teenagers during pregnancy and up to one year after giving birth, the Riverside Press-Enterprise reports. County health departments operate the program with oversight from the state Department of Public Health. Sarah Mack, a spokesperson for the Riverside County Department of Public Health, said the program provides a safety net for women who are uncertain about how to obtain prenatal care. The program"s nurses and social workers work to identify vulnerable groups with the goal of initiating care within the first trimester of pregnancy. The program aims to reduce incidences of low birthweight, premature delivery, maternal and infant mortality, preventable childhood diseases and disabling conditions.Gov. Arnold Schwarzenegger (R) has proposed eliminating more than $20 million in funding from the program to help reduce California"s estimated $24 billion budget deficit. Last week, the state Legislature"s joint budget conference introduced a counterproposal that would lower cuts to the program to $8 million.The most recent statistics from the state public health department show that nearly 16,000 California women who gave birth in 2006 had late or no prenatal care. More than 38,500 low-birthweight infants were born that year. Jim Lindley, director of the San Bernardino County Department of Public Health, said that Schwarzenegger"s proposal would amount to the elimination of "the bulk of funding" for the program. Mack said that Riverside County officials have identified scenarios to continue providing services if the state funding is eliminated. However, without the funding, "[m]ore people could fall through the safety net," Mack said, adding, "Those who need the program the most would be the most likely to fall through."Schwarzenegger spokesperson Lisa Page has said that the governor believes the state"s budget situation leaves him with little choice about making cuts (Hines, Riverside Press-Enterprise, 6/22).
Diagnostics

Researchers To Inject People With Diabetes With Cells From Pigs

Researchers are hoping that cells from pigs from a remote group of islands 300 miles from New Zealand could lead to a new treatment for Type 1 diabetes. Some of the pigs have been moved from the islands to mainland New Zealand, where they are being kept in fully enclosed sterile housing. The scientists are trialling the cell transplantation technique on a small group of people with unstable Type 1 diabetes in the hope of stimulating insulin production in their pancreases. Professor Bob Elliott who is running the trial has undertaken two similar studies in the past, one in 1995 and one in 2007. He says one volunteer from the first study continued producing insulin 12 years after transplantation - "proof of principle that this can work," he claims. Dr Iain Frame, Research Director at Diabetes UK, said: "Research into pig cell transplantation has been going on for several years, and is an exciting area of investigation. "However, two previous trials in 1995 and 2007 used only 15 volunteers and this small study will be carried out in just eight people in the first instance. It really is far too early to assume that this research will produce a real and lasting benefit to people with Type 1 diabetes in the near future. We will, however, be watching the progress of this area of research with great interest." Diabetes UK


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):